Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Norepinephrine vs dopamine for cardiogenic shock (28‑day mortality)
TCTR20210706003Not yet recruiting
- Sponsor
- Chulalongkorn University
- Start
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Trial of norepinephrine and dopamine in cardiogenic shock (2 arms), sponsored by Chulalongkorn University. Primary endpoint: 28-day all-cause mortality. Planned start Jul 2021; status: not yet recruiting.
02
Drugs
norepinephrinedopamine
03
Conditions
cardiogenic shock
Beyond the preview
Go deeper on TCTR20210706003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20210706003.